On April 20, 2017 Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, reported that data from a prospective biomarker analysis of a Phase 3 study using Progenics’ automated bone scan index (aBSI) will be presented in an oral session at the upcoming 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which will be held from June 2-6, 2017 in Chicago, Illinois (Press release, Progenics Pharmaceuticals, APR 20, 2017, View Source [SID1234518650]). In addition, a second abstract from a study on translating the Prostate Cancer Working Group (PCWG) criteria into a biomarker for prostate cancer will be presented in a poster session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The schedule for the presentations at ASCO (Free ASCO Whitepaper) is as follows:

Date & Time: Saturday, June 3, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Oral Abstract Presentation
Title: Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC)
Abstract No.: 5006

Date & Time: Monday, June 5, 2017, 1:15 PM-4:15 PM
Session Title: Genitourinary (Prostate) Cancer
Session Type: Poster Session
Title: Translating Prostate Cancer Working Group (PCWG) criteria into a quantitative progression biomarker in metastatic Castration Resistant Prostate Cancer (mCRPC)
Abstract No.: 5068

On April 20, 2017 Incyte Corporation (Nasdaq: INCY) reported that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in Chicago, Illinois from June 2-6, 2017 (Press release, Incyte, APR 20, 2017, View Source [SID1234518648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data presentations will include six abstracts from the ECHO-202/KEYNOTE-037 trial (NCT02178722), evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, in various tumor types (two oral presentations, three poster discussions and one poster session). KEYTRUDA is marketed by Merck (known as MSD outside the United States and Canada).

Additionally, data from ECHO-204 (NCT02327078) evaluating the safety and efficacy of epacadostat in combination with Opdivo (nivolumab) have been accepted as an oral presentation. Bristol-Myers Squibb holds development and commercial rights to Opdivo globally except for in the Ono Pharmaceutical territories of Japan, South Korea and Taiwan.

"These abstracts highlight the depth and potential of our growing clinical development portfolio of both immuno-oncology and targeted therapies," said Steven Stein, M.D., Chief Medical Officer, Incyte. "We are especially pleased to have new data from the ECHO-202 trial evaluating epacadostat plus pembrolizumab and initial data from the ECHO-204 trial evaluating epacadostat plus nivolumab accepted. These data contributed to our recent decisions to initiate additional pivotal Phase 3 studies with Merck and BMS."

Select key abstracts and presentations include:
Immuno-oncology abstracts

Efficacy and Safety of Epacadostat Plus Pembrolizumab Treatment of NSCLC: Preliminary Phase 1/2 Results of ECHO-202/KEYNOTE-037 (Abstract #9014, poster discussion)
Saturday, June 3, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board 340; Discussion 3:00 – 4:15 p.m. CT, Hall D2

Epacadostat Plus Pembrolizumab in Patients with Advanced RCC: Preliminary Phase 1/2 Results from ECHO-202/KEYNOTE-037 (Abstract #4515, poster discussion)
Sunday, June 4, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board #193; Discussion 11:30 – 12:45 p.m. CT, Arie Crown Theater

Efficacy/Safety of Epacadostat Plus Pembrolizumab in Triple-Negative Breast Cancer and Ovarian Cancer: Phase 1/2 ECHO-202 Study (Abstract #1103, poster session)
Sunday, June 4, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board #95

Epacadostat Plus Pembrolizumab in Patients with Advanced Urothelial Carcinoma: Preliminary Phase 1/2 Results of ECHO-202/KEYNOTE-037 (Abstract #4503, oral presentation)
Monday, June 5, 2017, 8:36 – 8:48 a.m. CT, Arie Crown Theater

Safety of Epacadostat 100 mg BID Plus Pembrolizumab 200 mg Q3W in Advanced Solid Tumors: Phase 2 Data from ECHO-202/KEYNOTE-037 (Abstract #3012, poster discussion)
Monday, June 5, 2017, 8:00 – 11:30 a.m. Hall A, Poster Board #107; Discussion 4:45 – 6:00 p.m. CT, Hall D1

Epacadostat Plus Nivolumab in Patients with Advanced Solid Tumors: Preliminary Phase 1/2 Results of ECHO-204 (Abstract #3003, oral presentation)
Monday, June 5, 2017, 2:15 – 2:27 p.m. CT, Hall D1

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients with solid tumors (Abstract #3005, oral presentation)
Monday, June 5, 2017, 2:39 p.m. – 2:51 p.m. CT, Hall D1

Epacadostat Plus Pembrolizumab in Patients with SCCHN: Preliminary Phase 1/2 Results from ECHO-202/KEYNOTE-037 (Abstract #6010, oral presentation)
Tuesday, June 6, 2017, 8:12 – 8:24 a.m. CT, S100a

Targeted therapy abstract
Ongoing Phase 1/2 Study of INCB050465 for Relapsed/Refractory (R/R) B-Cell Malignancies (CITADEL-101) (Abstract #7530, poster session)
Monday, June 5, 2017, 8:00 – 11:30 a.m. CT, Hall A, Poster Board #292
Full session details and data presentations at the ASCO (Free ASCO Whitepaper) 2017 annual meeting can be found here.

On April 20, 2017 Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, reported that new and updated data from two ongoing clinical trials of CMB305 and G100, as well as translational data examining the association of immunological response with improved survival in CMB305 and LV305 patients, will be presented in an oral and two posters presentations at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, June 2 – 6, 2017 in Chicago (Press release, Immune Design, APR 20, 2017, View Source [SID1234518647]). The ASCO (Free ASCO Whitepaper) presentation details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ORAL PRESENTATION

Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS)

Abstract # 11006
Session Title: Sarcoma
Date: Friday, June 2, 2017
Time: 3 p.m. — 6 p.m. CT (oral session)
Location: S100bc
Presenter: Neeta Somaiah, M.D., Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center
POSTER PRESENTATIONS

The Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients

Abstract # 3090
Session Title: Developmental Therapeutics—Immunotherapy
Date: Monday, June 5, 2017
Time: 8 a.m. — 11:30 a.m. CT (poster session)
Location: Hall A
Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research Center
Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma

Abstract # 7537
Session Title: Hematologic Malignancies — Lymphoma and Chronic Lymphocytic Leukemia
Date: Monday, June 5, 2017
Time: 8 a.m. — 11:30 a.m. CT (poster session)
Location: Hall A
Presenter: Christopher Flowers, M.D., Department of Hematology and Medical Oncology, Emory University School of Medicine
Additional data than those included in the abstracts may be included in the presentations.

On April 20, 2017 Genmab A/S (Nasdaq Copenhagen: GEN) reported that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, June 2 — 6 (Press release, Genmab, APR 20, 2017, View Source [SID1234518646]). These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO (Free ASCO Whitepaper) website with the full abstracts scheduled to be published on May 17, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO (Free ASCO Whitepaper) conference," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

List of abstracts:
Daratumumab:
Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or Bortezomib Plus Dexamethasone (DVd) in Relapsed or Refractory Multiple Myeloma Based on Cytogenic Risk Status — Oral presentation, Sunday, June 4, 11:45 AM — 11:57 AM CDT

Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma: An Open-Label, Phase Ib Study — Oral presentation, Sunday, June 4, 9:45 AM — 9:57 AM CDT

Safety and Efficacy of Daratumumab-based Regimens in Elderly (≥75 years) Patients with Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of POLLUX and CASTOR — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Daratumumab, Lenalidomide and Dexamethasone (DRd) versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (POLLUX) — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Daratumumab, Bortezomib and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety Update (CASTOR) — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

Randomized, Open-label Phase Ib/II Study of Atezolizumab with or without Daratumumab in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer — Trials in Progress Poster presentation, Saturday, June 3, 8:00 AM — 11:30 AM CDT

Comparative Efficacy of Multiple Myeloma Therapies for Treatment of First Relapse — A Systematic Literature Review and Network Meta-analysis — Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

HuMax-AXL-ADC:
GCT1021-01, a First-in-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax-AXL-ADC) in Patients with Solid Tumors — Trials in Progress Poster presentation, Monday, June 5, 8:00 AM — 11:30 AM CDT

On April 20, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that it will feature two clinical poster presentations during the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held June 2-6, in Chicago (Press release, Five Prime Therapeutics, APR 20, 2017, View Source [SID1234518645]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Number and Title: #4067, "Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer"
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Session Date and Time: Saturday, June 3, 2017, 8 – 11:30 a.m.
Location: Hall A, Poster Board Number: 59

Abstract Number and Title: #11078, "A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS)"
Poster Session: Sarcoma
Session Date and Time: Sunday, June 4, 2017, 8 – 11:30 a.m.
Location: Hall A, Poster Board Number: 401